One analyst takeaway from Shire’s 2018 outlook: Consensus earnings estimates probably need to come down. On Wednesday, the company said it was predicting $14.90 to $15.50 per share, a range that sits below the $15.94 Wall Street had been expecting. And that “initial 2018 outlook suggests EPS needs trimming,” Jefferies’ Peter Welford wrote in a note to clients.Original Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.